Cansortium Reports Third Quarter 2022 Financial Results

<br /> Cansortium Reports Third Quarter 2022 Financial Results<br />

PR Newswire


– Q3 Revenue up 42% YoY to

$22.1 Million



– Q3 Adjusted EBITDA up 15% QoQ and More Than 2x YoY to a Record

$11.7 Million

, with

$5.4 Million

of Cash from Operations –



MIAMI


,


Nov. 29, 2022


/PRNewswire/ –

Cansortium Inc.

(CSE: TIUM.U) (OTCQX: CNTMF) (“Cansortium” or the “Company”), a vertically-integrated cannabis company operating under the Fluent™ brand, today announced financial and operating results for the third quarter ended

September 30, 2022

. Unless otherwise indicated, all results are presented in U.S. dollars.

“We continued to execute on our profitability objectives during the third quarter, leading to another period of gross margin expansion and a record bottom line with strong cash flow generation,” said CEO

Robert Beasley

. “Had it not been for Hurricane Ian driving store closures in late September, we would have generated our 11

th

consecutive quarter of revenue growth, so I am very pleased with our team’s consistent effort to deliver on our goals.”

“As we exit the year and look to 2023, we expect to continue opening new stores in

Florida

while driving organic growth in our three

Pennsylvania

dispensaries. We also have plans to begin building out our footprint in

Texas

and look forward to growing our presence in the state in 2023.”



Q3 2022 Financial Highlights (vs. Q3 2021)

  • Revenue increased 42% to

    $22.1 million

    compared to

    $15.6 million

    .

  • Florida

    revenue increased 39% to

    $18.2 million

    compared to

    $13.1 million

    .
  • Adjusted gross profit[1] increased 71% to

    $16.7 million

    or 75.5% of revenue, compared to

    $9.8 million

    or 62.7% of revenue.
  • Adjusted EBITDA increased 140% to a record

    $11.7 million

    or 53.1% of revenue, compared to

    $4.9 million

    or 31.3% of revenue.
  • Cash from operations increased significantly to

    $5.4 million

    compared to cash used of

    $(4.2) million

    .
  • At

    September 30, 2022

    , the Company had approximately

    $9.1 million

    of cash and cash equivalents and

    $69.4 million

    of total debt, with approximately 252.3 million fully diluted shares outstanding (based on treasury stock method and share price on

    September 30, 2022

    ).


________________________



1

Adjusted gross profit is a non-IFRS financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Company calculates adjusted gross profit from gross profit plus (minus) the changes in fair value of biological assets, as presented in the consolidated statement of operations.




Operational Highlights

  • In

    Florida

    , the Company anticipates opening one new store by the end of 2022 and an additional three stores in the first half of 2023. All of these locations are currently under contract and going through construction.
  • During the third quarter, Cansortium temporarily closed twelve of its dispensaries in

    Florida

    during Hurricane Ian. All of the Company’s stores reopened in

    October 2022

    .
  • In

    Pennsylvania

    , the Company’s newest dispensary in

    Annville

    is ramping and achieved a record month of sales in

    October 2022

    .



2022 Outlook

The Company has continued to make progress on its targeted initiatives focused on growth and long-term shareholder value creation and is revising its previously issued revenue projection for 2022. Cansortium now expects revenue for 2022 to range between

$85



$90 million

(previously expected

$90



$95 million

). The Company also expects to close the year with Adjusted EBITDA exceeding its previously issued guidance of

$25



$28 million

for 2022.



Conference Call

The Company will host a conference call and live audio webcast today at

4:30 p.m. Eastern time

to discuss its financial and operational results, followed by a question-and-answer period.

Date:

Tuesday, November 29, 2022


Time:

4:30 p.m. Eastern time



Toll-free

dial-in number: (800) 319-4610

International dial-in number: (604) 638-5340

Conference ID: 10020760

Link:

Cansortium Conference Call

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Elevate IR at (720) 330-2829.

The conference call will also be available for replay via the News & Events section of the Company’s investor relations website at

https://investors.getfluent.com/

.



About Cansortium Inc.

Cansortium is a vertically-integrated cannabis company with licenses and operations in

Florida

,

Pennsylvania

and

Texas

. The Company operates under the Fluent™ brand and is dedicated to being one of the highest quality cannabis companies for the communities it serves. This is driven by Cansortium’s unrelenting commitment to operational excellence in cultivation, production, distribution and retail. The Company is headquartered in

Miami, Florida

.

Cansortium Inc.’s common shares trade on the CSE under the symbol “TIUM.U” and on the OTCQX Best Market under the symbol “CNTMF”. For more information about the Company, please visit

www.getfluent.com

.



Forward-Looking Information

Certain information in this news release may constitute forward-looking information within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent the Company’s expectations, estimates, and projections regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control.

Forward-looking information is necessarily based on many opinions, assumptions, and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in the public documents of the Company available at

www.sedar.com

. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

For further information:

www.getfluent.com

.



CANSORTIUM INC.



CONSOLIDATED STATEMENTS OF FINANCIAL POSITION



As of September 30, 2022 and December 31, 2021



(USD ‘000)



September 30,

2022



December 31,

2021



Assets


Current assets


Cash and cash equivalents


$                  9,099


$                   9,024


Trade receivable


53


26


Inventory, net


10,621


8,981


Biological assets


4,713


3,297


Investment held for sale


200


200


Prepaid expenses and other current assets


1,772


2,007


Total current assets


26,458


23,535


Property and equipment, net


32,738


34,160


Intangible assets, net


94,674


95,822


Right-of-use assets, net


30,018


19,169


Note receivable




4,886


Deposit




2,727


Goodwill


1,526


1,526


Other assets


769


632



Total assets



$              186,182



$               182,457



Liabilities


Current liabilities


Trade payable


9,009


8,518


Accrued liabilities


8,080


5,846


Income taxes payable


10,173


2,120


Derivative liabilities


8,981


3,960


Current portion of notes payable


43


619


Current portion of lease obligations


2,014


2,500


Total current liabilities


38,300


23,563




Notes payable


56,013


53,674


Lease obligations


33,233


21,091


Deferred tax liability


20,860


21,563


Other long-term liabilities


750




Total liabilities



149,156



119,891



Shareholders’ equity


Share capital


180,792


180,657


Share-based compensation reserve


6,329


6,176


Equity conversion feature


6,677


4,933


Warrants


28,939


28,869


Accumulated deficit


(185,378)


(157,649)


Foreign currency translation reserve


(334)


(421)


Total shareholders’ equity


37,026


62,565



Total liabilities and shareholders’ equity



$              186,182



$               182,457



CANSORTIUM INC.



STATEMENT OF OPERATIONS



FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020



For the three months ended

September 30,



For the nine months ended

September 30,



2022



2021



2022



2021


Revenue, net of discounts


$                22,100


$                 15,568


$             64,228


$            47,153


Cost of goods sold


5,419


5,805


20,990


16,956


Gross profit before fair value adjustments


16,681


9,763


43,238


30,197


Fair value adjustments on inventory sold


(9,605)


(5,113)


(25,023)


(14,433)


Unrealized gain on changes in fair value of biological assets


2,558


6,113


13,224


11,768


Gross profit


9,634


10,763


31,439


27,532


Expenses


General and administrative


2,188


2,084


7,348


8,241


Share-based compensation


53


731


153


4,248


Sales and marketing


4,556


4,033


12,833


11,094


Depreciation and amortization


1,656


1,649


5,014


4,727


Total expenses


8,453


8,497


25,348


28,310


(Loss) income from operations


1,181


2,266


6,091


(778)


Other expense (income)


Finance costs, net


4,422


3,383


11,922


11,233


Loss (gain) on change in fair value of derivative liability


313




5,021


(1,551)


Equity loss on investment in associate










Private Placement issuance expense




890




7,530


Loss on debt settlement




(10,794)


1,136


(42)


Loss on disposal of assets


(22)


(20)


(22)


30


Other (income) expense


(1)


7


(373)


(124)


Total other expense


4,712


(6,534)


17,684


17,076


Loss before income taxes


(3,531)


8,800


(11,593)


(17,854)


Income tax expense


2,026


1,437


7,542


4,868


Net income (loss) from continuing operations


(5,557)


7,363


(19,135)


(22,722)


Net loss (income) from discontinued operations


19


2


8,594


33


Net income (loss)


$                (5,576)


$                   7,361


$            (27,729)


#


$          (22,755)


Other comprehensive gain that may be reclassified


to profit or loss in subsequent years


Exchange differences on translation of foreign operations and reporting currency


62


(22)


87


(33)


Comprehensive income (loss)


$                (5,514)


$                   7,339


$            (27,642)


#


$          (22,788)


Net income (loss) per share


Basic and diluted – continuing operations


$                  (0.02)


$                     0.03


$                (0.11)


$              (0.10)


Weighted average  number of shares


Basic number of shares


252,276,742


248,405,314


252,230,588


221,637,004


Diluted number of shares


309,136,061


303,101,057


308,192,639


265,312,794



CANSORTIUM INC.



STATEMENTS OF CASH FLOWS



(USD ‘000)



For the nine months ended September 30,



2022



2021



Operating activities


Net loss from continuing operations


$                        (27,729)


$                        (22,755)


Adjustments to reconcile net loss to net cash provided by (used in) operating activities:


Unrealized gain on changes in fair value of biological assets


(13,224)


(11,768)


Realized gain on changes in fair value of biological assets


25,023


14,433


Share-based compensation


153


3,883


Depreciation and amortization


9,534


7,529


Accretion and interest of convertible debentures




3,457


Interest and debt issuance costs of term loan


9,359




Interest income on notes receivable


(71)




Loss on disposal of assets


(22)


30


Loss on debt settlement


1,136




Discontinued operations


8,594


33


Change in fair market value of derivative


5,021


(1,551)


Interest on lease liabilities


2,546


1,911


Deferred tax expense


(703)


(852)


Changes in operating assets and liabilities:


Trade receivable


(27)


(153)


Inventory


1,185


(4,969)


Biological assets


(15,495)


(3,859)


Prepaid expenses and other current assets


(477)


1,632


Right of Use Assets/Liabilities


236




Other assets




(122)


Trade payable


333


(123)


Accrued liabilities


2,060


(396)


Income taxes payable


8,053


(9,553)


Net cash provided by (used in) operating activities


15,486


(23,193)



Investing activities


Purchases of property and equipment


(5,439)


(15,210)


Purchase of intangible assets




(318)


Payment of notes receivable


119


1,477


Proceeds from sale of property and equipment




29


Advances for notes receivable


(94)


(1,802)


Net cash used in investing activities


(5,414)


(15,824)



Financing activities


Proceeds from issuance of shares and warrants




23,730


Proceeds from issuance of debt, net of loan issuance costs




63,086


Proceeds from issuance of convertible debenture and warrants


4,710




Payment of lease obligations


(4,226)


(3,342)


Exercise of Options


135




Exercise of warrants




1,365


Principal repayments of notes payable




(35,373)


Repayments of principal and interest of Senior Secure Term loan


(10,703)




Net cash provided by (used in) financing activities


(10,084)


49,466


Effect of foreign exchange on cash and cash equivalents


87


(33)


Net increase (decrease) in cash and cash equivalents


75


10,416


Cash and cash equivalents, beginning of period


9,024


3,392


Cash and cash equivalents, end of period


$                            9,099


$                          13,808



CANSORTIUM INC.



ADJUSTED EBITDA RECONCILIATION



(USD ‘000)



Three months ended



September



September



30, 2022



30, 2021



Variance


Net loss


$           (5,576)


$              7,361


$       (12,937)


Finance costs, net


4,422


3,383


1,039


Income taxes


2,026


1,437


589


Depreciation and amortization


3,464


2,844


620


EBITDA


$            4,336


$            15,025


$       (10,689)



Three months ended



September

30, 2022



September

30, 2021



Variance


EBITDA


$            4,336


$            15,025


$       (10,689)


Change in fair value of biological assets


7,047


(1,000)


8,047


Change in fair market value of derivative


313




313


Loss on debt settlement




(10,794)


10,794


Private placement issuance expense




890


(890)


Share-based compensation


53


731


(678)


Discontinued operations


19


2


17


Loss on disposal of assets


(22)


(20)


(2)


Other non-recurring expense/(income)


(1)


52


(53)


Adjusted EBITDA


$          11,745


$              4,886


$          6,859

Cision
View original content to download multimedia:

https://www.prnewswire.com/news-releases/cansortium-reports-third-quarter-2022-financial-results-301689408.html

SOURCE Cansortium Inc